What’s Really Driving the Direct-to-Patient Boom?

Once viewed as an emerging channel, Direct-to-Patient (DTP) models are increasingly becoming a core component of commercial strategy as life sciences manufacturers look for new ways to improve patient access, reduce friction, and create more direct relationships with the people they serve. 

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, discusses what’s fueling the growth of DTP and why more organizations are investing in direct engagement models in a recent interview with Pharmaceutical Commerce.

A Shift in Commercial Strategy

Today, manufacturers are looking beyond traditional channels to reach patients more efficiently than ever before.

Many organizations are recognizing that portions of their addressable patient populations remain difficult to identify, engage, and support through conventional commercial models. As a result, DTP strategies are helping companies create more direct pathways between patients and care.

By bringing together commerce, patient engagement, and support services, manufacturers can gain better visibility into the patient journey while helping patients navigate potential barriers to treatment.

Patient Services Enable Better Access

While commercial objectives may be accelerating DTP adoption, patient services are helping make these models successful.

The patient journey often includes multiple handoffs, administrative hurdles, and access challenges that can delay therapy initiation or affect persistence over time.

DTP models provide an opportunity to create a more connected experience by bringing together patient support resources, educational tools, and access solutions that help reduce friction throughout treatment.

Why the Momentum Continues

The continued growth of DTP reflects a broader industry shift toward more personalized and patient-centric healthcare experiences.

Manufacturers are evaluating how direct engagement models can:

• Improve patient access

• Support therapy initiation and adherence

• Create greater visibility across the patient journey

• Deliver a more connected commercial experience

The future of DTP will be defined by the ability to integrate commercial strategy, patient services, and data-driven insights into a seamless experience.

Organizations that can successfully connect these elements will be better positioned to support patients while creating more effective and sustainable commercialization models.

Learn more about EVERSANA DIRECT™ Commercialization offerings